Hypertension-induced renal injury is characterized by inflammation, fibrosis and proteinuria. Previous studies have demonstrated that N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) inhibits renal damage following diabetes mellitus and anti-glomerular basement membrane nephritis. However, its effects on low renin hypertensive nephropathy are not known. Thus, we hypothesized that Ac-SDKP has renal protective effects on DOCA-salt hypertensive mice, decreasing inflammatory cell infiltration, matrix deposition and albuminuria. We uninephrectomized 16-week old C57BL/6J mice and treated them with either placebo, deoxycorticosterone acetate-salt (10mg/10gm body weight sub cutaneous) and 1% NaCl + 0.2% KCl in drinking water (DOCA-salt), or DOCA-salt + Ac-SDKP (800 μg/Kg/day) for 12 weeks. We measured blood pressure, urine albumin, glomerular matrix and renal collagen content, monocyte/macrophage infiltration and glomerular nephrin expression. Treatment with DOCA-salt significantly increased blood pressure (P<0.01), which remained unaltered by Ac-SDKP. Ac-SDKP decreased DOCA-salt-induced renal collagen deposition, glomerular matrix expansion and monocyte/macrophage infiltration. Moreover, DOCA-salt-induced increase in albuminuria was normalized by Ac-SDKP (controls, 10.8 ± 1.7; DOCA-salt, 41 ± 5; DOCA-salt + Ac-SDKP, 13 ± 3 μg/10gmBW/24hr; p< 0.001, DOCA-salt vs. DOCA-salt + Ac-SDKP). Loss of nephrin reportedly causes excess urinary protein excretion; therefore we determined whether Ac-SDKP inhibits proteinuria by restoring nephrin expression in the glomerulus of hypertensive mice. DOCA-salt significantly downregulated glomerular nephrin expression (controls, 37 ± 8; DOCA-salt, 10 ± 1.5 % of glomerular area; p < 0.01), which was partially reversed by Ac-SDKP (23 ± 4.0 % of glomerular area; p = 0.065, DOCA-salt vs. DOCAsalt + Ac-SDKP). We concluded that Ac-SDKP prevents hypertension-induced inflammatory cell infiltration, collagen deposition, nephrin downregulation and albuminuria, which could lead to renoprotection in hypertensive mice.